Cluster composition

Functions

CategoryNameIntersectionWithQueryPValueGenesInTermGenesInQueryGenesInTermInQueryID
GeneOntologyMolecularFunctionDNA exonuclease activity, producing 5'-phosphomonoesters

POLE DCLRE1B

3.42e-0425222GO:0016895
GeneOntologyMolecularFunctionDNA exonuclease activity

POLE DCLRE1B

3.71e-0426222GO:0004529
GeneOntologyMolecularFunctionmolecular condensate scaffold activity

CARD8 SOS1

9.71e-0442222GO:0140693
GeneOntologyMolecularFunctionguanyl-nucleotide exchange factor activity

TRIO RIC1 SOS1

2.00e-03231223GO:0005085
GeneOntologyMolecularFunctionexonuclease activity, active with either ribo- or deoxyribonucleic acids and producing 5'-phosphomonoesters

POLE DCLRE1B

2.11e-0362222GO:0016796
GeneOntologyMolecularFunctionDNA nuclease activity

POLE DCLRE1B

2.45e-0367222GO:0004536
GeneOntologyMolecularFunctionenzyme regulator activity

TRIO BMP2K PARP9 CARD8 RIC1 SOS1

3.52e-031418226GO:0030234
HumanPhenoPancolitis

CARD8 DCLRE1B

2.08e-054102HP:0033256
DomainSpectrin_repeat

TRIO PLEC

5.27e-0429222IPR002017
DomainSpectrin/alpha-actinin

TRIO PLEC

6.43e-0432222IPR018159
DomainSPEC

TRIO PLEC

6.43e-0432222SM00150
DomainGDS_CDC24_CS

TRIO SOS1

9.56e-0439222IPR001331
DomainDH_1

TRIO SOS1

2.48e-0363222PS00741
DomainRhoGEF

TRIO SOS1

2.88e-0368222SM00325
DomainRNaseH-like_dom

ZBED6 POLE

2.96e-0369222IPR012337
DomainDH_2

TRIO SOS1

3.05e-0370222PS50010
DomainRhoGEF

TRIO SOS1

3.05e-0370222PF00621
DomainDH-domain

TRIO SOS1

3.13e-0371222IPR000219
Domain-

TRIO SOS1

3.13e-03712221.20.900.10
DomainPH_dom-like

TRIO PARP9 SOS1

1.31e-02426223IPR011993
Pubmed

Distinct behavioral and neuropathological abnormalities in transgenic mouse models of HD and DRPLA.

HTT ATN1

3.82e-07222211442350
Pubmed

Is the 31 CAG repeat allele of the spinocerebellar ataxia 1 (SCA1) gene locus non-specifically associated with trinucleotide expansion diseases?

HTT ATN1

2.29e-06422211807410
Pubmed

Searching for mutation in the JPH3, ATN1 and TBP genes in Polish patients suspected of Huntington's disease and without mutation in the IT15 gene.

HTT ATN1

2.29e-06422218651325
Pubmed

A dual-activity topoisomerase complex regulates mRNA translation and turnover.

TRIO CUL9 POLE RIC1 SFI1 HTT PLEC

3.60e-06110522735748872
Pubmed

Polyglutamine tracts regulate beclin 1-dependent autophagy.

HTT ATN1

5.72e-06622228445460
Pubmed

Comparison of the number of triplets in SCA1, MJD/SCA3, HD, SBMA, DRPLA, MD, FRAXA and FRDA genes in schizophrenic patients and a healthy population.

HTT ATN1

8.01e-06722211121205
Pubmed

Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract.

HTT ATN1

1.37e-0592229535906
Pubmed

The RNA binding protein MEX3A promotes tumor progression of breast cancer by post-transcriptional regulation of IGFBP4.

TRIO ZBED6 PARP9 PLEC

5.21e-0533222437433992
Pubmed

The Repeat Expansion Diseases: The dark side of DNA repair.

HTT ATN1

9.59e-052322226002199
Pubmed

Chr21 protein-protein interactions: enrichment in proteins involved in intellectual disability, autism, and late-onset Alzheimer's disease.

TRIO TUBGCP5 CUL9 ASTN1 PLEC SOS1

1.13e-04128522635914814
Pubmed

Proteome-scale mapping of binding sites in the unstructured regions of the human proteome.

RIC1 PLEC SOS1 ATN1

1.41e-0443022435044719
Pubmed

The human cytoplasmic dynein interactome reveals novel activators of motility.

TRIO BMP2K CARD8 MCU PLEC

1.63e-0485322528718761
Pubmed

A proteomics strategy to elucidate functional protein-protein interactions applied to EGF signaling.

PLEC SOS1

2.12e-043422212577067
Pubmed

Mutation of ARHGAP9 in patients with coronary spastic angina.

TRIO SOS1

2.65e-043822219911011
Pubmed

Cytoplasmic Metadherin (MTDH) provides survival advantage under conditions of stress by acting as RNA-binding protein.

CUL9 CARD8 PLEC

3.24e-0421422322199357
Pubmed

A protein interaction landscape of breast cancer.

TRIO BMP2K CUL9 MCU

6.16e-0463422434591612
GeneFamilyPleckstrin homology domain containing|Rho guanine nucleotide exchange factors|C2 domain containing

TRIO SOS1

8.46e-0466122722
CoexpressionGSE21927_SPLENIC_C26GM_TUMOROUS_VS_4T1_TUMOR_MONOCYTES_DN

TUBGCP5 PARP9 RIC1 SOS1

2.00e-05196224M7590
CoexpressionTABULA_MURIS_SENIS_AORTA_FIBROBLAST_OF_CARDIAC_TISSUE_AGEING

DISP3 BMP2K MCU PLEC ATN1

2.81e-04723225MM3672
CoexpressionPETRETTO_HEART_MASS_QTL_CIS_UP

TRIO PLEC

3.29e-0432222M17037
CoexpressionGSE7768_OVA_ALONE_VS_OVA_WITH_LPS_IMMUNIZED_MOUSE_WHOLE_SPLEEN_6H_UP

TUBGCP5 CUL9 SMPD2

3.71e-04169223M6851
CoexpressionKAAB_FAILED_HEART_ATRIUM_UP

TRIO PLEC

4.16e-0436222M8009
CoexpressionGSE27241_WT_VS_RORGT_KO_TH17_POLARIZED_CD4_TCELL_TREATED_WITH_DIGOXIN_UP

POLE RIC1 SOS1

4.46e-04180223M8239
CoexpressionE2F3_UP.V1_UP

RTN4RL1 POLE DCLRE1B

5.22e-04190223M2706
CoexpressionGSE40274_CTRL_VS_FOXP3_AND_HELIOS_TRANSDUCED_ACTIVATED_CD4_TCELL_UP

TRIO BMP2K SFI1

5.88e-04198223M9119
CoexpressionHALLMARK_MITOTIC_SPINDLE

TRIO TUBGCP5 SOS1

5.97e-04199223M5893
CoexpressionGSE5589_LPS_VS_LPS_AND_IL6_STIM_IL10_KO_MACROPHAGE_45MIN_DN

CUL9 DCLRE1B ATN1

5.97e-04199223M6632
CoexpressionGSE21670_TGFB_VS_IL6_TREATED_STAT3_KO_CD4_TCELL_UP

RSPH4A TRIO SOS1

5.97e-04199223M7448
CoexpressionGSE9037_CTRL_VS_LPS_1H_STIM_BMDM_UP

TRIO CUL9 SOS1

6.06e-04200223M5800
CoexpressionGSE43863_TH1_VS_TFH_EFFECTOR_CD4_TCELL_DN

TRIO ZBED6 PLEC

6.06e-04200223M9763
CoexpressionGSE11961_UNSTIM_VS_ANTI_IGM_AND_CD40_STIM_6H_FOLLICULAR_BCELL_UP

BMP2K ASTN1 MCU

6.06e-04200223M9333
CoexpressionGSE11961_FOLLICULAR_BCELL_VS_MEMORY_BCELL_DAY7_UP

PARP9 HTT SOS1

6.06e-04200223M9338
CoexpressionGSE40068_CXCR5POS_BCL6POS_TFH_VS_CXCR5NEG_BCL6NEG_CD4_TCELL_UP

TRIO RTN4RL1 ATN1

6.06e-04200223M9258
CoexpressionGSE40273_GATA1_KO_VS_WT_TREG_DN

BMP2K SFI1 PLEC

6.06e-04200223M9133
CoexpressionGSE40274_FOXP3_VS_FOXP3_AND_LEF1_TRANSDUCED_ACTIVATED_CD4_TCELL_DN

RTN4RL1 ZBED6 PARP9

6.06e-04200223M9188
CoexpressionGSE7460_CTRL_VS_TGFB_TREATED_ACT_FOXP3_MUT_TCONV_UP

MCU PLEC SOS1

6.06e-04200223M5698
CoexpressionGSE5099_UNSTIM_VS_MCSF_TREATED_MONOCYTE_DAY7_DN

SMPD2 MCU PLEC

6.06e-04200223M6585
CoexpressionGSE27786_LSK_VS_MONO_MAC_DN

ASTN1 MCU PLEC

6.06e-04200223M4765
CoexpressionGSE39820_TGFBETA1_IL6_VS_TGFBETA1_IL6_IL23A_TREATED_CD4_TCELL_UP

BMP2K TUBGCP5 HTT

6.06e-04200223M5617
ToppCellCV-Severe-7|CV / Virus stimulation, Condition and Cluster

ZBED6 SFI1 HTT ZNF235

1.57e-061762243de0c7d77210049e5616db21eed1490a17a5ec2d
ToppCellCV-Severe-7|Severe / Virus stimulation, Condition and Cluster

ZBED6 SFI1 HTT ZNF235

1.60e-0617722482fdd6185b368f54f03de389427cbe3071d21a99
ToppCellfacs-Marrow-B-cells-24m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DISP3 TUBGCP5 RTN4RL1

5.03e-051472239d7e965fe61bd7b31e09c4b2129a5a98c36f4811
ToppCellfacs-Marrow-B-cells-24m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

DISP3 TUBGCP5 RTN4RL1

5.03e-0514722338552953ff65a0fc20bee6ef57dc5885306ad18b
ToppCelldroplet-Trachea-3m-Mesenchymal-fibroblast-fibroblast_of_trachea-|3m / method, tissue, age, lineage, sublineage, cell ontologies, cell type and subtype

POLE PARP9 ZNF235

7.34e-05167223774f3264318b002d0df5d06d41d645366038d0bf
ToppCellfacs-Marrow-T-cells-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

7.88e-051712236a0fafb8fd9fc7671618eeb2bf528ce8ce86b794
ToppCellfacs-Marrow-T-cells-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

7.88e-05171223e02b5831768dbb1b68998b672e55c9680ab0cc86
ToppCell5'-Parenchyma_lung-Immune_Myeloid-Myeloid_monocytic-classical_monocyte-Classical_monocytes-Classical_monocytes_L.1.2.0.3|5' / 5'-vs-3', Tissue groups, Lineages, Lineage subclass, Cell_type2, Cell_subtype2_L4.5

BMP2K CARD8 ZNF235

8.72e-0517722368f1139fc378f351e3b9e9f392aacb150025bf03
ToppCelldroplet-Marrow-nan-3m-Lymphocytic-nan|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.02e-0517922387a69f9f83b8f0c028a4874acb238f2e079bf51f
ToppCelldroplet-Marrow-nan-3m-Lymphocytic|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.02e-05179223dcaf2191134a586d50ebaf67dcf5b815b54a722b
ToppCellfacs-Marrow-B-cells-3m-Myeloid-macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.17e-0518022382965ed1b72a1873c24dd4553d39681596057316
ToppCellfacs-Marrow-B-cells-3m-Myeloid-CD4+_macrophage|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.17e-05180223bf8d13d4db1af55b8c9fe16aaccf8743e000e005
ToppCellfacs-Marrow-B-cells-3m-Myeloid|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.17e-05180223839defb40f7cfb2711e9025194de636533f51bcd
ToppCelldroplet-Marrow-nan-3m-Lymphocytic-precursor_B_cell|Marrow / Spleen_Marrow_Thymus - method, tissue, subtissue, age, lineage, cell ontology and free annotation

BMP2K TUBGCP5 RTN4RL1

9.17e-05180223df60970520fba2ac0639faa54096766d07418ca4
ToppCellwk_15-18-Hematologic-Myeloid-APOE+_Mac1|wk_15-18 / Celltypes from embryonic and fetal-stage human lung

BMP2K CUL9 DCLRE1B

1.22e-0419822388182ad964db88cf85b3e3a64929d07d59a923c2
Drugserinal

SMPD2 CARD8

1.33e-056222CID000051574
DrugMethotrimeprazine maleat salt [7104-38-3]; Up 200; 9uM; PC3; HT_HG-U133A

TRIO BMP2K ZNF235 ATN1

2.93e-051882243701_UP
DrugBeta-Escin [11072-93-8]; Down 200; 3.2uM; MCF7; HT_HG-U133A

CARD8 SFI1 PLEC ATN1

3.12e-051912243890_DN
DrugPF-00562151-00 [351320-12-2]; Down 200; 10uM; PC3; HT_HG-U133A

SMPD2 CARD8 DCLRE1B PLEC

3.18e-051922245959_DN
DrugNaphazoline hydrochloride [550-99-2]; Up 200; 16.2uM; HL60; HG-U133A

BMP2K SFI1 HTT PLEC

3.38e-051952241966_UP
DrugDapsone [80-08-0]; Down 200; 16.2uM; PC3; HT_HG-U133A

BMP2K SMPD2 CARD8 DCLRE1B

3.38e-051952241827_DN
DrugPyrantel tartrate [33401-94-4]; Up 200; 11.2uM; MCF7; HT_HG-U133A

TUBGCP5 SFI1 ZNF235 ATN1

3.38e-051952242260_UP
DrugTelenzepine dihydrochloride [147416-96-4]; Down 200; 9uM; HL60; HT_HG-U133A

BMP2K TUBGCP5 SMPD2 POLE

3.45e-051962242388_DN
Drug(cis-) Nanophine [5072-45-7]; Up 200; 26.8uM; MCF7; HT_HG-U133A

TRIO CUL9 SFI1 HTT

3.45e-051962243889_UP
DrugFluticasone propionate [80474-14-2]; Down 200; 8uM; MCF7; HT_HG-U133A

BMP2K CUL9 SOS1 ATN1

3.45e-051962247348_DN
DrugTrimethobenzamide hydrochloride [554-92-7]; Down 200; 9.4uM; PC3; HT_HG-U133A

TRIO ASTN1 SMPD2 ATN1

3.45e-051962244100_DN
Drug(-)-Eseroline fumarate salt [104015-29-4]; Up 200; 12uM; MCF7; HT_HG-U133A

BMP2K CUL9 PLEC SOS1

3.45e-051962247027_UP
DrugRiboflavine [83-88-5]; Up 200; 10.6uM; HL60; HG-U133A

BMP2K SFI1 PLEC SOS1

3.52e-051972241767_UP
DrugFuraltadone hydrochloride [3759-92-0]; Down 200; 11uM; HL60; HT_HG-U133A

BMP2K CUL9 SFI1 PLEC

3.52e-051972242554_DN
DrugDemeclocycline hydrochloride [64-73-3]; Down 200; 8uM; PC3; HT_HG-U133A

TRIO SMPD2 SFI1 ATN1

3.59e-051982243706_DN
DrugNitrocaramiphen hydrochloride; Down 200; 10.8uM; MCF7; HT_HG-U133A

BMP2K CUL9 SMPD2 SFI1

3.59e-051982246504_DN
DrugPhenethicillin potassium salt [132-93-4]; Up 200; 10uM; HL60; HT_HG-U133A

SFI1 PLEC ZNF235 ATN1

3.73e-052002242542_UP
Drugmethylene diphosphonate

PARP9 HTT

3.56e-0429222CID000016124
Drugprimidone

SOS1 ATN1

5.82e-0437222CID000004909
DrugMonensin sodium salt [22373-78-0]; Up 200; 5.8uM; PC3; HT_HG-U133A

TRIO ZNF235 ATN1

7.03e-041832233704_UP
DrugPrenylamine lactate [69-43-2]; Up 200; 9.6uM; HL60; HG-U133A

SMPD2 HTT PLEC

7.14e-041842231737_UP
DrugRapamycin; Up 200; 0.1uM; MCF7; HT_HG-U133A_EA

TRIO CARD8 SFI1

7.25e-041852231022_UP
Drug0297417-0002B [362658-29-5]; Up 200; 10uM; MCF7; HT_HG-U133A

BMP2K SMPD2 SFI1

7.37e-041862236900_UP
DrugGanciclovir [82410-32-0]; Down 200; 15.6uM; MCF7; HT_HG-U133A

BMP2K PLEC ATN1

7.48e-041872233368_DN
DrugSecurinine [5610-40-2]; Down 200; 18.4uM; HL60; HT_HG-U133A

TUBGCP5 CUL9 SFI1

7.48e-041872232729_DN
DrugThioguanosine [85-31-4]; Down 200; 12.6uM; MCF7; HT_HG-U133A

BMP2K TUBGCP5 SOS1

7.48e-041872234989_DN
Druglomustine; Down 200; 100uM; PC3; HT_HG-U133A

TRIO TUBGCP5 PLEC

7.60e-041882237050_DN
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; MCF7; HT_HG-U133A

TRIO CARD8 PLEC

7.60e-041882234845_DN
DrugResveratrol [501-36-0]; Down 200; 17.6uM; PC3; HT_HG-U133A

TRIO BMP2K SFI1

7.72e-041892235084_DN
Drug0173570-0000 [211245-44-2]; Down 200; 10uM; PC3; HT_HG-U133A

TRIO SMPD2 PLEC

7.72e-041892233690_DN
DrugClioquinol [130-26-7]; Up 200; 13uM; MCF7; HT_HG-U133A

SMPD2 SFI1 SOS1

7.96e-041912236461_UP
DrugEtofenamate [30544-47-9]; Up 200; 10.8uM; MCF7; HT_HG-U133A

TRIO SFI1 ATN1

8.08e-041922234108_UP
DrugOrlistat; Up 200; 10uM; PC3; HT_HG-U133A

TRIO SFI1 DCLRE1B

8.08e-041922236388_UP
Drugalpha-estradiol; Down 200; 0.01uM; MCF7; HT_HG-U133A_EA

TRIO HTT PLEC

8.20e-041932231048_DN
Drug0179445-0000 [211246-22-9]; Up 200; 10uM; PC3; HT_HG-U133A

TRIO BMP2K ZNF235

8.20e-041932234289_UP
DrugBoldine [476-70-0]; Up 200; 12.2uM; MCF7; HT_HG-U133A

BMP2K CUL9 ATN1

8.20e-041932234122_UP
DrugGuanabenz acetate [23256-50-0]; Down 200; 13.8uM; PC3; HG-U133A

TRIO HTT DCLRE1B

8.20e-041932231961_DN
DrugMuramic acid, N-acetyl [10597-89-4]; Up 200; 13.6uM; MCF7; HT_HG-U133A

TRIO SFI1 ATN1

8.20e-041932233262_UP
DrugSolasodine [126-17-0]; Down 200; 9.6uM; PC3; HT_HG-U133A

BMP2K CARD8 SFI1

8.20e-041932234305_DN
DrugGSK-3beta Inhibitor VIII; Up 200; 10uM; PC3; HT_HG-U133A

BMP2K CUL9 PLEC

8.20e-041932237097_UP
DrugGossypol [303-45-7]; Down 200; 7.8uM; HL60; HT_HG-U133A

TUBGCP5 POLE PLEC

8.20e-041932232202_DN
Drugfelodipine; Down 200; 10uM; MCF7; HT_HG-U133A_EA

SMPD2 CARD8 PLEC

8.20e-04193223965_DN
DrugAjmaline [4360-12-7]; Up 200; 12.2uM; MCF7; HT_HG-U133A

TRIO BMP2K SFI1

8.20e-041932232899_UP
DrugRapamycin; Down 200; 0.1uM; HL60; HT_HG-U133A

CUL9 SMPD2 SFI1

8.32e-041942236201_DN
Drugnordihydroguaiaretic acid; Down 200; 1uM; PC3; HT_HG-U133A

BMP2K POLE CARD8

8.32e-041942231223_DN
DrugICI 182,780; Up 200; 0.01uM; MCF7; HT_HG-U133A

BMP2K PLEC ATN1

8.32e-041942236955_UP
DrugAcemetacin [53164-05-9]; Up 200; 9.6uM; MCF7; HT_HG-U133A

SMPD2 SFI1 ATN1

8.32e-041942237442_UP
DrugBromperidol [10457-90-6]; Down 200; 9.6uM; MCF7; HT_HG-U133A

TRIO SMPD2 PLEC

8.32e-041942237457_DN
DrugPrimaquine diphosphate [63-45-6]; Down 200; 8.8uM; PC3; HT_HG-U133A

TRIO BMP2K CARD8

8.32e-041942234263_DN
DrugEthoxyquin [91-53-2]; Up 200; 18.4uM; MCF7; HT_HG-U133A

CUL9 SFI1 ATN1

8.32e-041942233846_UP
DrugAzapropazone [13539-59-8]; Down 200; 13.4uM; HL60; HT_HG-U133A

CUL9 SMPD2 SFI1

8.32e-041942233143_DN
Drugdiclofenac sodium; Down 200; 10uM; MCF7; HG-U133A

SMPD2 PLEC ATN1

8.45e-04195223333_DN
DrugImipramine hydrochloride [113-52-0]; Up 200; 12.6uM; MCF7; HT_HG-U133A

TRIO SFI1 ZNF235

8.45e-041952235440_UP
DrugPalmatine chloride [3486-67-7]; Down 200; 10.4uM; MCF7; HT_HG-U133A

TRIO BMP2K PLEC

8.45e-041952234957_DN
DrugThiocolchicoside [602-41-5]; Down 200; 7uM; MCF7; HT_HG-U133A

TRIO BMP2K POLE

8.45e-041952235520_DN
DrugAmoxicillin [26787-78-0]; Up 200; 11uM; MCF7; HT_HG-U133A

SFI1 ZNF235 ATN1

8.45e-041952235385_UP
Drug5707885; Up 200; 50uM; PC3; HT_HG-U133A

SFI1 ZNF235 ATN1

8.45e-041952236390_UP
DrugTranylcypromine hydrochloride [1986-47-6]; Down 200; 23.6uM; MCF7; HT_HG-U133A

BMP2K SFI1 PLEC

8.45e-041952232264_DN
DrugFlumethasone [2135-17-3]; Down 200; 9.8uM; MCF7; HT_HG-U133A

TRIO SFI1 ATN1

8.45e-041952234734_DN
DrugLoracarbef [121961-22-6]; Up 200; 10.8uM; HL60; HT_HG-U133A

BMP2K SFI1 PLEC

8.45e-041952232970_UP
DrugAcacetin [480-44-4]; Down 200; 14uM; PC3; HT_HG-U133A

TRIO BMP2K ATN1

8.45e-041952234324_DN
DrugPropoxycaine hydrochloride [550-83-4]; Down 200; 12uM; MCF7; HT_HG-U133A

CUL9 SMPD2 ATN1

8.45e-041952233583_DN
DrugMetrizamide [31112-62-6]; Down 200; 5uM; MCF7; HT_HG-U133A

SMPD2 SFI1 ATN1

8.45e-041952234156_DN
DrugHemicholinium bromide [312-45-8]; Down 200; 7uM; PC3; HT_HG-U133A

TRIO SFI1 HTT

8.45e-041952236739_DN
Drugarachidonyl trifluoromethyl ketone; Up 200; 10uM; MCF7; HG-U133A

TRIO PLEC ATN1

8.45e-04195223327_UP
DrugTestosterone propionate [57-85-2]; Down 200; 11.6uM; PC3; HT_HG-U133A

SMPD2 ZNF235 ATN1

8.45e-041952234676_DN
Drugradicicol; Down 200; 0.1uM; MCF7; HT_HG-U133A_EA

SMPD2 CARD8 PLEC

8.45e-04195223953_DN
Drug5286656; Up 200; 50uM; MCF7; HT_HG-U133A_EA

BMP2K SFI1 ZNF235

8.45e-04195223889_UP
Drug17-DMAG; Down 200; 0.1uM; MCF7; HT_HG-U133A

CUL9 SMPD2 ATN1

8.45e-041952235573_DN
DrugPNU-0293363 [326823-19-2]; Down 200; 10uM; PC3; HT_HG-U133A

TRIO BMP2K PLEC

8.58e-041962236563_DN
Drug(S)-propranolol hydrochloride [4199-10-4]; Up 200; 13.6uM; HL60; HT_HG-U133A

SMPD2 SFI1 PLEC

8.58e-041962232961_UP
DrugTolazamide [1156-19-0]; Down 200; 12.8uM; HL60; HT_HG-U133A

BMP2K PLEC SOS1

8.58e-041962232482_DN
DrugPargyline hydrochloride [306-07-0]; Up 200; 20.4uM; HL60; HG-U133A

SFI1 SOS1 ATN1

8.58e-041962231418_UP
DrugPNU-0251126 [267429-19-6]; Up 200; 1uM; PC3; HT_HG-U133A

ASTN1 SFI1 ATN1

8.58e-041962233692_UP
Drug5162773; Down 200; 7uM; MCF7; HT_HG-U133A_EA

BMP2K HTT ATN1

8.58e-04196223892_DN
DrugAcetaminophen [103-90-2]; Up 200; 26.4uM; HL60; HT_HG-U133A

TRIO SFI1 ATN1

8.58e-041962233025_UP
DrugChlorprothixene hydrochloride [6469-93-8]; Down 200; 11.4uM; MCF7; HT_HG-U133A

SMPD2 PLEC SOS1

8.58e-041962232627_DN
DrugPivmecillinam hydrochloride [32887-03-9]; Down 200; 8.4uM; PC3; HT_HG-U133A

BMP2K CUL9 CARD8

8.58e-041962237312_DN
DrugUrsolic acid [77-52-1]; Down 200; 8.8uM; MCF7; HT_HG-U133A

SMPD2 SFI1 PLEC

8.58e-041962237181_DN
DrugAlfadolone acetate [23930-37-2]; Down 200; 10.2uM; MCF7; HT_HG-U133A

BMP2K SMPD2 SFI1

8.58e-041962236506_DN
DrugMethoxy-8-psoralen [298-81-7]; Down 200; 18.6uM; MCF7; HT_HG-U133A

TRIO BMP2K HTT

8.58e-041962235007_DN
DrugSC-58125; Down 200; 10uM; SKMEL5; HG-U133A

SMPD2 PLEC ATN1

8.58e-04196223507_DN
DrugDroperidol [548-73-2]; Down 200; 10.6uM; PC3; HT_HG-U133A

BMP2K CARD8 ATN1

8.58e-041962234629_DN
Drug5279552; Down 200; 22uM; MCF7; HT_HG-U133A_EA

TRIO SMPD2 PLEC

8.58e-04196223960_DN
Drugradicicol; Up 200; 0.1uM; MCF7; HT_HG-U133A

TRIO CUL9 ZNF235

8.58e-041962235947_UP
DrugGemfibrozil [25812-30-0]; Down 200; 16uM; PC3; HT_HG-U133A

BMP2K CARD8 SFI1

8.58e-041962232113_DN
Druggenistein; Up 200; 10uM; MCF7; HT_HG-U133A

TRIO SFI1 ATN1

8.58e-041962235232_UP
DrugICI182,780; Down 200; 1uM; PC3; HT_HG-U133A

TRIO BMP2K ATN1

8.58e-041962237495_DN
DrugMifepristone [84371-65-3]; Down 200; 9.4uM; MCF7; HT_HG-U133A

SFI1 HTT PLEC

8.58e-041962237183_DN
DrugTridihexethyl chloride; Up 200; 11.4uM; MCF7; HT_HG-U133A

CUL9 CARD8 ZNF235

8.58e-041962235486_UP
DrugTriflupromazine hydrochloride [1098-60-8]; Down 200; 10.2uM; MCF7; HT_HG-U133A

SMPD2 CARD8 SFI1

8.58e-041962231691_DN
DrugDiclofenac sodium [15307-79-6]; Down 200; 12.6uM; PC3; HT_HG-U133A

TRIO BMP2K TUBGCP5

8.58e-041962235861_DN
DrugThyroxine (L) [51-48-9]; Down 200; 5.2uM; HL60; HT_HG-U133A

SMPD2 HTT DCLRE1B

8.58e-041962231312_DN
DrugHymecromone [90-33-5]; Down 200; 22.8uM; MCF7; HT_HG-U133A

BMP2K SFI1 ATN1

8.58e-041962233383_DN
DrugChlorpheniramine maleate [113-92-8]; Up 200; 10.2uM; MCF7; HT_HG-U133A

SFI1 ZNF235 ATN1

8.58e-041962232217_UP
DrugHydrochlorothiazide [58-93-5]; Down 200; 13.4uM; MCF7; HT_HG-U133A

TRIO SMPD2 SFI1

8.58e-041962231487_DN
DrugIsopropamide iodide [71-81-8]; Down 200; 8.4uM; MCF7; HT_HG-U133A

CUL9 SMPD2 PLEC

8.70e-041972236781_DN
DrugPilocarpine nitrate [148-72-1]; Down 200; 14.8uM; MCF7; HT_HG-U133A

BMP2K CUL9 CARD8

8.70e-041972235341_DN
DrugDicyclomine hydrochloride [67-92-5]; Down 200; 11.6uM; MCF7; HT_HG-U133A

BMP2K SFI1 ATN1

8.70e-041972234405_DN
DrugPseudopelletierine hydrochloride [6164-62-1]; Up 200; 21uM; HL60; HG-U133A

SFI1 PLEC ATN1

8.70e-041972231774_UP
DiseaseIntellectual Disability

TRIO ASTN1 HTT ATN1

2.53e-04447214C3714756
Diseasehepatocyte growth factor measurement

HTT SOS1

4.48e-0444212EFO_0006903

Protein segments in the cluster

PeptideGeneStartEntry
RGHLIVQLQELLHHW

DISP3

706

Q9P2K9
QRLALEQQQWLHAHH

ATN1

1151

P54259
WRLQQLHLQHRHPHQ

BMP2K

446

Q9NSY1
HLLHRHLQVSKQWIQ

DCLRE1B

56

Q9H816
QWLENGTLLFHIHHQ

ASTN1

111

O14525
RLLLHENQLQWVHHK

RTN4RL1

201

Q86UN2
LSTLLGHRHWHVVQI

RIC1

471

Q4ADV7
HAWIQRILSLQNHHI

PARP9

531

Q8IXQ6
QHHRTVHQRIASWQN

MCU

46

Q8NE86
LHLHSNLAAVWDQHL

TUBGCP5

236

Q96RT8
HLQRHNHLLWLSPTA

POLE

1676

Q07864
HRVAQAWELAQFIHH

SMPD2

151

O60906
HDSEHLTWLIVNHIQ

HTT

1911

P42858
QHLALDLQHHEQWLV

CARD8

216

Q9Y2G2
HLLAHSHWGAEQLLQ

CUL9

2026

Q8IWT3
NWREIHHLVFHVANI

BVES

36

Q8NE79
LSNWVHHVQHILSQG

RSPH4A

541

Q5TD94
HQHSVLHRALQAWVT

SFI1

646

A8K8P3
QLRVLNVCRHWVEHH

SOS1

686

Q07889
AQHQALVTLWHQLHV

PLEC

1011

Q15149
TLQRHLQARHSPHWT

ZBED6

171

P86452
RFNWSLNLHNHQRVH

ZNF235

551

Q14590
IHEVLHHQRQLENIW

TRIO

541

O75962
HHQRQLENIWQHRKV

TRIO

546

O75962